VYNE Therapeutics Inc. (VYNE) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does VYNE Therapeutics Inc. Do?
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. VYNE Therapeutics Inc. (VYNE) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David Domzalski and employs approximately 30 people. With a market capitalization of $20M, VYNE is one of the notable companies in the Healthcare sector.
VYNE Therapeutics Inc. (VYNE) Stock Rating — Reduce (April 2026)
As of April 2026, VYNE Therapeutics Inc. receives a Reduce rating with a composite score of 28.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.VYNE ranks #2,392 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, VYNE Therapeutics Inc. ranks #294 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
VYNE Stock Price and 52-Week Range
VYNE Therapeutics Inc. (VYNE) currently trades at $0.61. The stock lost $0.00 (0.4%) in the most recent trading session. The 52-week high for VYNE is $1.99, which means the stock is currently trading -69.4% from its annual peak. The 52-week low is $0.28, putting the stock 117.5% above its annual trough. Recent trading volume was 101K shares, suggesting relatively thin trading activity.
Is VYNE Overvalued or Undervalued? — Valuation Analysis
VYNE Therapeutics Inc. (VYNE) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.71x, versus the sector average of 2.75x. The price-to-sales ratio is 33.49x, compared to 1.66x for the average Healthcare stock.
At current multiples, VYNE Therapeutics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
VYNE Therapeutics Inc. Profitability — ROE, Margins, and Quality Score
VYNE Therapeutics Inc. (VYNE) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -129.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -119.1% versus the sector average of -33.1%.
On a margin basis, VYNE Therapeutics Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -7888.2% (sector: -66.1%). Net profit margin stands at -6850.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -29.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
VYNE Debt, Balance Sheet, and Financial Health
VYNE Therapeutics Inc. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 12.53x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $22M.
VYNE has a beta of 0.84, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for VYNE Therapeutics Inc. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
VYNE Therapeutics Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, VYNE Therapeutics Inc. reported revenue of $590,000 and earnings per share (EPS) of $-0.62. Net income for the quarter was $-36M. Gross margin was 100.0%. Operating income came in at $-40M.
In FY 2025, VYNE Therapeutics Inc. reported revenue of $570,000 and earnings per share (EPS) of $-0.62. Net income for the quarter was $-26M. Revenue grew 13.8% year-over-year compared to FY 2024. Operating income came in at $-30M.
In Q2 2025, VYNE Therapeutics Inc. reported revenue of $69,000 and earnings per share (EPS) of $-0.13. Net income for the quarter was $-6M. Revenue grew -65.2% year-over-year compared to Q2 2024. Operating income came in at $-8M.
In Q1 2025, VYNE Therapeutics Inc. reported revenue of $202,000 and earnings per share (EPS) of $-0.20. Net income for the quarter was $-9M. Revenue grew 106.1% year-over-year compared to Q1 2024. Operating income came in at $-9M.
Over the past 8 quarters, VYNE Therapeutics Inc. has demonstrated a growth trajectory, with revenue expanding from $98,000 to $590,000. Investors analyzing VYNE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
VYNE Dividend Yield and Income Analysis
VYNE Therapeutics Inc. (VYNE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
VYNE Momentum and Technical Analysis Profile
VYNE Therapeutics Inc. (VYNE) has a momentum factor score of 37/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.
VYNE vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, VYNE Therapeutics Inc. (VYNE) ranks #294 out of 838 stocks based on the Blank Capital composite score. This places VYNE in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing VYNE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VYNE vs S&P 500 (SPY) comparison to assess how VYNE Therapeutics Inc. stacks up against the broader market across all factor dimensions.
VYNE Next Earnings Date
No upcoming earnings date has been announced for VYNE Therapeutics Inc. (VYNE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy VYNE? — Investment Thesis Summary
The quantitative profile for VYNE Therapeutics Inc. suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 37/100, a headwind for near-term performance. High volatility (stability score 31/100) increases portfolio risk.
In summary, VYNE Therapeutics Inc. (VYNE) earns a Reduce rating with a composite score of 28.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VYNE stock.
Related Resources for VYNE Investors
Explore more research and tools: VYNE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VYNE head-to-head with peers: VYNE vs AZN, VYNE vs SLGL, VYNE vs VMD.